Sell-Side Forecast & Transaction Structuring Leading to Licensing Deal
Sell-Side Forecast & Transaction Structuring Leading to Licensing Deal
A private biotechnology company sought an independent perspective on the prospects of its therapeutic programs and technology platform under a series of potential transaction structure scenarios.
The company was contemplating a potential IPO or M&A and licensing/collaboration transactions.
Conducted primary and secondary market research for each disease area and indication relevant to the company’s various therapeutics programs.
Developed a forecast model with sensitivity analyses to assess the reasonableness of high, mid and low forecast scenarios.
Created valuation modules assessing various transaction structures, including multiple licensing/collaboration transactions across multiple programs, territories and indications.
RNA provided its findings to the company’s head of business development in preparation of negotiations with investors and transaction counterparties.
The company ultimately closed a licensing and collaboration transaction with a large biopharmaceutical company, and then went public shortly thereafter.
Enter your email address below to receive updates from RNA Advisors.